BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 17299076)

  • 1. Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids.
    Menconi F; Marinò M; Pinchera A; Rocchi R; Mazzi B; Nardi M; Bartalena L; Marcocci C
    J Clin Endocrinol Metab; 2007 May; 92(5):1653-8. PubMed ID: 17299076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioiodine ablation of postsurgical thyroid remnants after treatment with recombinant human TSH (rhTSH) in patients with moderate-to-severe graves' orbitopathy (GO): a prospective, randomized, single-blind clinical trial.
    Moleti M; Violi MA; Montanini D; Trombetta C; Di Bella B; Sturniolo G; Presti S; Alibrandi A; Campennì A; Baldari S; Trimarchi F; Vermiglio F
    J Clin Endocrinol Metab; 2014 May; 99(5):1783-9. PubMed ID: 24432992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of Graves' orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial.
    Leo M; Marcocci C; Pinchera A; Nardi M; Megna L; Rocchi R; Latrofa F; Altea MA; Mazzi B; Sisti E; Profilo MA; Marinò M
    J Clin Endocrinol Metab; 2012 Jan; 97(1):E44-8. PubMed ID: 22031515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total thyroid ablation in Graves' orbitopathy.
    Menconi F; Leo M; Vitti P; Marcocci C; Marinò M
    J Endocrinol Invest; 2015 Aug; 38(8):809-15. PubMed ID: 25740065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial effect of low-dose radioiodine ablation for Graves' orbitopathy: results of a retrospective study.
    Lanzolla G; Menconi F; Nicolì F; Posarelli C; Maglionico MN; Figus M; Nardi M; Marcocci C; Marinò M
    J Endocrinol Invest; 2021 Dec; 44(12):2575-2579. PubMed ID: 33844165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of thyroidectomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of graves' ophthalmopathy.
    Moleti M; Mattina F; Salamone I; Violi MA; Nucera C; Baldari S; Lo Schiavo MG; Regalbuto C; Trimarchi F; Vermiglio F
    Thyroid; 2003 Jul; 13(7):653-8. PubMed ID: 12964971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients.
    Leo M; Sabini E; Ionni I; Sframeli A; Mazzi B; Menconi F; Molinaro E; Bianchi F; Brozzi F; Santini P; Elisei R; Nardi M; Vitti P; Marcocci C; Marinò M
    J Endocrinol Invest; 2018 Mar; 41(3):357-361. PubMed ID: 28856610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relation between therapy options for Graves' disease and the course of Graves' ophthalmopathy: a systematic review and meta-analysis.
    Li HX; Xiang N; Hu WK; Jiao XL
    J Endocrinol Invest; 2016 Nov; 39(11):1225-1233. PubMed ID: 27220843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
    Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy.
    Sisti E; Menconi F; Leo M; Profilo MA; Mautone T; Mazzi B; Rocchi R; Latrofa F; Nardi M; Vitti P; Marcocci C; Marinò M
    J Endocrinol Invest; 2015 Jun; 38(6):661-8. PubMed ID: 25596664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural history of graves' orbitopathy after treatment.
    Menconi F; Leo M; Sabini E; Mautone T; Nardi M; Sainato A; Sellari-Franceschini S; Vitti P; Marcocci C; Marinò M
    Endocrine; 2017 Aug; 57(2):226-233. PubMed ID: 27709471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves' ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial.
    Brammen L; Riss P; Lukas J; Gessl A; Dunkler D; Li S; Leisser A; Rezar-Dreindl S; Eibenberger K; Selberherr A; Scheuba C; Papp A
    Trials; 2018 Sep; 19(1):495. PubMed ID: 30219088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time course of Graves' ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study.
    De Bellis A; Conzo G; Cennamo G; Pane E; Bellastella G; Colella C; Iacovo AD; Paglionico VA; Sinisi AA; Wall JR; Bizzarro A; Bellastella A
    Endocrine; 2012 Apr; 41(2):320-6. PubMed ID: 22169963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of mild, moderate-to-severe and very severe Graves' orbitopathy.
    Marcocci C; Marinò M
    Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):325-37. PubMed ID: 22632369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between Graves' ophthalmopathy and type of treatment of Graves' hyperthyroidism.
    Marcocci C; Bartalena L; Bogazzi F; Bruno-Bossio G; Pinchera A
    Thyroid; 1992; 2(2):171-8. PubMed ID: 1525588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graves' orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis.
    Vannucchi G; Campi I; Covelli D; Dazzi D; Currò N; Simonetta S; Ratiglia R; Beck-Peccoz P; Salvi M
    J Clin Endocrinol Metab; 2009 Sep; 94(9):3381-6. PubMed ID: 19567525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent graves' orbitopathy: a retrospective cohort study.
    Lai A; Sassi L; Compri E; Marino F; Sivelli P; Piantanida E; Tanda ML; Bartalena L
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1333-7. PubMed ID: 20061414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Graves' ophthalmopathy and 131I therapy.
    Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Mazzi B; Rocchi R; Barbesino G; Pinchera A
    Q J Nucl Med; 1999 Dec; 43(4):307-12. PubMed ID: 10731781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy.
    Bartalena L
    J Clin Endocrinol Metab; 2011 Mar; 96(3):592-9. PubMed ID: 21190983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves' Disease: results of a pilot study.
    Lanzolla G; Ricci D; Nicolì F; Sabini E; Sframeli A; Brancatella A; Mantuano M; Dottore GR; Bucci I; Figus M; Nardi M; Latrofa F; Marcocci C; Marinò M
    J Endocrinol Invest; 2020 Dec; 43(12):1759-1768. PubMed ID: 32583374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.